株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非典型溶血性尿毒症症候群 - パイプライン製品の分析

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 321898
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.65円で換算しております。
Back to Top
非典型溶血性尿毒症症候群 - パイプライン製品の分析 Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2019
出版日: 2019年01月31日 ページ情報: 英文 96 Pages
概要

非典型溶血性尿毒症症候群は、主に腎機能に影響を及ぼす疾患で、すべての年代に発症します。異常な血栓が腎臓の毛細血管に形成され、腹痛、疲労感、焦燥感、血尿といった症状が挙げられます。

当レポートでは、非典型溶血性尿毒症症候群に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

非典型溶血性尿毒症症候群の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Adienne Pharma & Biotech
  • Alnylam Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Omeros Corporation

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ALN-CC5
  • CCX-168
  • ET-006
  • ETR-001
  • Mubodina
  • OMS-72

パイプライン製品の最新動向

開発休止中のプロジェクト

付録

図表

図表

List of Tables

  • Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Achillion Pharmaceuticals Inc, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Akari Therapeutics Plc, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Amgen Inc, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx Inc, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Greenovation Biotech GmbH, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corp, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Ra Pharmaceuticals Inc, H1 2019
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects, H1 2019

List of Figures

  • Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11063IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H1 2019, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape.

Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine and confusion.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 4 respectively.

Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Overview
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals Inc
    • Akari Therapeutics Plc
    • Alexion Pharmaceuticals Inc
    • Amgen Inc
    • ChemoCentryx Inc
    • Greenovation Biotech GmbH
    • Omeros Corp
    • Ra Pharmaceuticals Inc
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drug Profiles
    • ACH-4471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacopan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Age-Related Macular Degeneration, Atypical Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRN-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nomacopan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ravulizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ravulizumab next generation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MASP2 for Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zilucoplan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 28, 2019: Alexion announces positive top-line results from phase 3 study Of ULTOMIRIS (Ravulizumab-Cwvz) in complement inhibitor-naive patients with Atypical Hemolytic Uremic Syndrome (AHUS)
      • Jan 17, 2019: Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
      • Nov 30, 2018: Akari Therapeutics announces new data highlighting differentiation of drug candidate Coversin
      • Aug 08, 2018: Ra Pharmaceuticals announces early completion of enrollment in gMG Phase 2 program
      • Jun 15, 2018: Ra Pharmaceuticals presents data on oral, small molecule complement inhibitors and phase 2 RA101495 SC program in PNH at the 23rd congress of the European Hematology Association
      • Apr 26, 2018: FDA Grants Breakthrough Therapy Designation to Omeros' MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
      • Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
      • Jan 03, 2018: Omeros Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
      • Oct 16, 2017: Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation
      • Mar 27, 2017: Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
      • Oct 27, 2016: Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
      • Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
      • Sep 06, 2016: Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
      • Jul 28, 2016: Omeros Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
      • May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top